menu
    • menu
    [{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Ludwig Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Temozolomide","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"Ludwig Enterprises","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ludwig Enterprises \/ Ludwig Enterprises","highestDevelopmentStatusID":"4","companyTruncated":"Ludwig Enterprises \/ Ludwig Enterprises"},{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Emerson Urology Associates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Mycobacterium Bovis Bacille Calmette-Guerin Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ludwig Enterprises","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ludwig Enterprises \/ Emerson Urology Associates","highestDevelopmentStatusID":"1","companyTruncated":"Ludwig Enterprises \/ Emerson Urology Associates"},{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ludwig Enterprises","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ludwig Enterprises \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ludwig Enterprises \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Ludwig Enterprises

    Menu

    Ludwig Enterprises

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ludwig Enterprises

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ludwig Enterprises

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : University of Central florida

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study

                            Details : The net proceeds will be used to fund a preclinical study on Glioblastoma (GBM), an incurable brain cancer, to potentially increase the efficacy of Merck's FDA approved drug Temodar (temozolomide).

                            Product Name : Temodar

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 27, 2024

                            Lead Product(s) : Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : University of Central florida

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ludwig Enterprises

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ludwig Enterprises

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amino Acids Mixture

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ludwig Enterprises Announces Launch of New Nutraceutical and Strategic Marketing Plan

                            Details : NuGenea is a nutraceutical formulated with 20 different ingredients which have been scientifically shown to help fight chronic inflammation, which is a causative factor in illnesses such as cancer, diabetes, COPD and heart disease.

                            Product Name : NuGenea

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 25, 2023

                            Lead Product(s) : Amino Acids Mixture

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ludwig Enterprises

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ludwig Enterprises

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mycobacterium Bovis Bacille Calmette-Guerin Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Emerson Urology Associates

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ludwig Enterprises and Emerson Urology Associates Plan Bladder Cancer BCG Immunotherapy Study

                            Details : Bacillus Calmette-Guérin (BCG) is a cancer vaccine that uses weakened bacteria to stimulate the immune system. BCG (mycobacterium bovis bacille calmette-guerin vaccine) has received U.S. FDA approval for the treatment of early-stage bladder cancer.

                            Product Name : BCG

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 20, 2022

                            Lead Product(s) : Mycobacterium Bovis Bacille Calmette-Guerin Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Emerson Urology Associates

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth